Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

Inclusion Criteria:

* Relapsed SCLC
* Etoposide with cisplatin or carboplatin was first-line chemotherapy in SCLC
* At least 30 days after the completion of first-line chemotherapy
* Either sex, age between 18 to 70 years
* Expected life time ≥ 3 months
* Performance status ECOG grade 0-1. Patients with PS 2 whose general condition is explained by obstructive/bulky disease likely to improve after the first cycle of chemotherapy can be included at the discretion of the local investigator. Patients with PS 2 as a result of comorbid conditions will be excluded.
* Adequate bone marrow and organ function as defined below:

Neutrophils ≥ 1.5 × 109/L, platelets 80 × 109/L, hemoglobin ≥80 g/L; AST and ALT ≤2× the upper limit of the institutional normal range, total bilirubin ≤1.25× the upper limit of the institutional normal range; Creatinineconcentration ≤120 μmol/L

* Had measurable or assessable disease

Exclusion Criteria:

* Concomitant with other malignant disease
* Pregnancy or lactation at the time of enrollment
* Any contraindications for chemotherapy
* Received target therapy or immunotherapy